Logo image of MOLN

MOLECULAR PARTNERS AG -ADR (MOLN) Stock Fundamental Analysis

USA - NASDAQ:MOLN - US60853G1067 - ADR

3.77 USD
+0.08 (+2.17%)
Last: 9/19/2025, 8:00:01 PM
Fundamental Rating

3

Overall MOLN gets a fundamental rating of 3 out of 10. We evaluated MOLN against 538 industry peers in the Biotechnology industry. While MOLN seems to be doing ok healthwise, there are quite some concerns on its profitability. MOLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MOLN has reported negative net income.
In the past year MOLN has reported a negative cash flow from operations.
In the past 5 years MOLN reported 4 times negative net income.
In the past 5 years MOLN reported 4 times negative operating cash flow.
MOLN Yearly Net Income VS EBIT VS OCF VS FCFMOLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.49%, MOLN is in line with its industry, outperforming 55.64% of the companies in the same industry.
The Return On Equity of MOLN (-50.67%) is better than 65.62% of its industry peers.
Industry RankSector Rank
ROA -43.49%
ROE -50.67%
ROIC N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
MOLN Yearly ROA, ROE, ROICMOLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

MOLN's Gross Margin of 99.80% is amongst the best of the industry. MOLN outperforms 98.52% of its industry peers.
MOLN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for MOLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
MOLN Yearly Profit, Operating, Gross MarginsMOLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MOLN has been increased compared to 1 year ago.
Compared to 5 years ago, MOLN has more shares outstanding
Compared to 1 year ago, MOLN has an improved debt to assets ratio.
MOLN Yearly Shares OutstandingMOLN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MOLN Yearly Total Debt VS Total AssetsMOLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MOLN has an Altman-Z score of 0.04. This is a bad value and indicates that MOLN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MOLN (0.04) is better than 60.07% of its industry peers.
MOLN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
MOLN has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.04
ROIC/WACCN/A
WACC4.92%
MOLN Yearly LT Debt VS Equity VS FCFMOLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 9.35 indicates that MOLN has no problem at all paying its short term obligations.
MOLN has a Current ratio of 9.35. This is in the better half of the industry: MOLN outperforms 79.85% of its industry peers.
MOLN has a Quick Ratio of 9.35. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
MOLN has a Quick ratio of 9.35. This is amongst the best in the industry. MOLN outperforms 80.04% of its industry peers.
Industry RankSector Rank
Current Ratio 9.35
Quick Ratio 9.35
MOLN Yearly Current Assets VS Current LiabilitesMOLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

MOLN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
Looking at the last year, MOLN shows a very negative growth in Revenue. The Revenue has decreased by -29.38% in the last year.
Measured over the past years, MOLN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)18.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.06%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -3.98% on average over the next years.
Based on estimates for the next years, MOLN will show a very strong growth in Revenue. The Revenue will grow by 97.30% on average per year.
EPS Next Y7.01%
EPS Next 2Y5.2%
EPS Next 3Y15.32%
EPS Next 5Y-3.98%
Revenue Next Year-75%
Revenue Next 2Y65.83%
Revenue Next 3Y128.15%
Revenue Next 5Y97.3%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MOLN Yearly Revenue VS EstimatesMOLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
MOLN Yearly EPS VS EstimatesMOLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MOLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MOLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MOLN Price Earnings VS Forward Price EarningsMOLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MOLN Per share dataMOLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

MOLN's earnings are expected to grow with 15.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.2%
EPS Next 3Y15.32%

More info and screens

0

5. Dividend

5.1 Amount

MOLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (9/19/2025, 8:00:01 PM)

3.77

+0.08 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-25 2025-08-25/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners45.02%
Inst Owner Change0.1%
Ins Owners4%
Ins Owner ChangeN/A
Market Cap139.02M
Analysts82.22
Price Target14.14 (275.07%)
Short Float %0.09%
Short Ratio9.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.62%
PT rev (3m)10.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.27
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS0.17
BVpS3.63
TBVpS3.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.49%
ROE -50.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.44%
Cap/Sales 18.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.35
Quick Ratio 9.35
Altman-Z 0.04
F-Score2
WACC4.92%
ROIC/WACCN/A
Cap/Depr(3y)41.08%
Cap/Depr(5y)46.5%
Cap/Sales(3y)8.93%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.06%
EPS Next Y7.01%
EPS Next 2Y5.2%
EPS Next 3Y15.32%
EPS Next 5Y-3.98%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-75%
Revenue Next 2Y65.83%
Revenue Next 3Y128.15%
Revenue Next 5Y97.3%
EBIT growth 1Y-0.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.56%
EBIT Next 3Y20.63%
EBIT Next 5YN/A
FCF growth 1Y9.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.98%
OCF growth 3YN/A
OCF growth 5YN/A